Seagen Inc.
Q2 2022 Earnings Call
Jul 28, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and welcome to the Seagen Second Quarter 2022 Financial Results Conference Call. [Operator instructions] Please note this event is being recorded. I'd now like to turn the conference over to Doug Maffei, vice president of investor relations. Please go ahead.
Doug Maffei -- Vice President, Investor Relations
Thank you, operator, and good afternoon, everyone. I'm pleased to welcome you to Seagen's second quarter 2022 financial results conference call. This afternoon, we issued a press release with our results. The press release and supporting slides are available on our website in the Investors Section, Events and Presentations page.
Speakers on today's call will be Roger Dansey, interim chief executive officer and chief medical officer; Todd Simpson, chief financial officer; and Chip Romp, executive vice president, commercial U.S. Following our prepared remarks, we'll open the line for questions. We aim to keep this call to one hour. [Operator instructions] Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the company's 2022 financial outlook, anticipated product sales, revenues, costs and expenses.
Future developments related to legal matters, potential clinical and regulatory milestones, including data readouts and regulatory submissions, potential marketing and reimbursement approvals and commercial performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty in forecasting sales, revenues, costs and expenses, impacts related to the COVID-19 pandemic, and the uncertainty associated with legal disputes, and with the pharmaceutical development and regulatory approval process. More information about the risks and uncertainties faced by Seagen is contained under the caption risk factors included in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2022, filed with the Securities and Exchange Commission, and the company's subsequent reports filed with the SEC.
Now I'll turn the call over to Roger.
Roger Dansey -- Interim Chief Executive Officer and Chief Medical Officer
Thank you, Doug. Good afternoon, everyone, and welcome to our second quarter earnings call. I was recently appointed Interim CEO, and I am honored and privileged to lead such an extraordinary company. Along with my seasoned colleagues, I am deeply committed to continuing our mission of bringing transformative medicines to market that make a meaningful difference in the lives of people with cancer.